Claims for Patent: 6,113,894

Summary for Patent: 6,113,894

Title:	Ophthalmic compositions and process of using
Abstract:	An ophthalmic composition and process for treating blepharitis employing the composition of 0.5-10% of available nonionic surfactant in water to emulsify and remove lipids from the corneal surface.
Inventor(s):	Smith; S. Gregory (Yorklyn, DE)
Assignee:
Application Number:	09/146,683
Patent Claims:	1. In a process for the treatment of blepharitis comprising contacting the surface of the cornea having lipids on its surface with an aqueous composition consisting of: greater than zero to about 1% of at least one viscosity-adjusting agent, greater than zero to about 0.1% of a preservative agent, greater than zero to about 0.3% of at least one buffering agent, and devoid of lecithin, said ingredients being present in an amount of from 0.07 to 1.4% by weight, said percent being based upon weight per volume, the improvement which comprises incorporating into said composition an amount of nonionic surfactant having a viscosity of about 400-3500 centipoises, a surface tension of about 40-50 dynes/centimeter and an HLB value of at least 12 in sterile water sufficient to provide 0.5-10% by weight of available nonionic surfactant to dissolve said lipids selected from the group consisting of disodium oleamide, cocoamphocarboxyl and a polysorbate; to permit the mucin and aqueous layers of the natural tear to contact the complete surface of the cornea, wherein symptoms of dry eye are overcome for extended periods of time rather than temporarily. 2. A process as in claim 1 wherein said viscosity-adjusting agent is hydroxy propyl methyl chloride. 3. A process as in claim 1 wherein said tonicity-adjusting agent is selected from the group consisting of sodium chloride, potassium chloride and dextrose. 4. A process as in claim 1 wherein said preservative agent is benzalkonium chloride. 5. A process as in claim 1 wherein said buffering agent is selected from the group consisting of monobasic sodium phosphate and anhydrous dibasic sodium phosphate. 6. A process as in claim 1 wherein the amount of said nonionic surfactant is sufficient to provide about 1-5% of available nonionic surfactant. 7. A process as in claim 1 wherein said nonionic surfactant is selected from the group consisting of a polyalkylene oleic ester of a sorbitol anhydride; disodium oleamide polyethylene glycol-sulfosuccinate and cocamphocarboxyl glycinate.

Details for Patent 6,113,894

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2015-01-23